Navigation Links
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Date:5/21/2008

Three of Four HUMIRA Patients from CHARM Study in Remission at One Year

Maintained Remission at Two Years

ABBOTT PARK, Ill., May 21 /PRNewswire-FirstCall/ -- Results from an open-label extension study of two Abbott pivotal studies, CHARM and GAIN, demonstrate that adult moderate-to-severe Crohn's patients treated with HUMIRA(R) (adalimumab) achieved long-term clinical remission and clinical response, respectively, according to data presentations today at Digestive Disease Week(R) (DDW) in San Diego. DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Patients from CHARM and GAIN were followed through into a non-placebo controlled, ongoing open-label extension (OLE) trial. Patients from CHARM were followed a total of two years, and patients from the 4-week GAIN study were followed a total of one year.

The CHARM extension data demonstrated that three out of four patients (77 percent) taking HUMIRA, who were in remission at the end of the one-year pivotal study, maintained clinical remission for an additional year. The GAIN data showed that, of patients with a clinical response at four weeks, approximately 65 percent remained in clinical response at one year, and 40 percent were in clinical remission at one year. Response was measured by change in Crohn's Disease Activity Index (CDAI), a weighted composite score of eight clinical factors that evaluate patient wellness, including daily number of liquid or very soft stools, severity of abdominal pain, levels of general well-being and other measures. Clinical remission was measured as a score of less than 150 and clinical response was measured as a decline of at least 70 points from baseline.

Crohn's disease is a serious, chronic, inflammatory bowel disease that affects more than 500,000 Americans. It affects people of all ages but it is primarily a disease
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
4. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
5. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
6. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
7. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
10. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Mich. and PHOENIX ... corporation established to bring cutting-edge next-generation sequencing and ... cancer patients, today announced a collaboration with TESARO, ... to characterize patient tissue samples from clinical trials ... or resistant to TESARO,s TSR-011.  This may lead to ...
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today announced ... platform during a special event at the company,s office ... on September 5, 2014. The event, which will start ... ApolloDx website, www.apollodx.com .    "We ... said Jared Bauer , Co-Founder and Managing Partner ...
(Date:8/20/2014)... Fla. , Aug. 20, 2014  Glades Drugs, an ... , is proud to announce its expansion into a new ... which will feature an 8,000-square-foot office space and state of ... accepting applications for 100 open positions for the new facility. ... 4560 Lantana Road will serve as the chain,s corporate headquarters ...
Breaking Medicine Technology:Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2
... 28 Danaher Corporation (NYSE: DHR ) announced ... Comas will be presenting at the Goldman Sachs Global Industrials ... at 10:15 a.m. EDT. The company also announced that President ... presenting at the Robert W. Baird Industrial Conference in Chicago, ...
... The U.S. Food and Drug Administration today ... of adults with schizophrenia. (Logo: ... ) Schizophrenia affects about 1 ... and older, in a given year. The most ...
Cached Medicine Technology:FDA Approves Latuda to Treat Schizophrenia in Adults 2
(Date:8/20/2014)... 20, 2014 According to a ... "Multiplexed Diagnostics Market (Technologies: Very High, High, Medium, ... Disease Diagnosis, Oncology, Autoimmune Diseases, Cardiac, Allergies and ... Trends and Forecast, 2013 - 2019", the global ... billion in 2012 and is expected to grow ...
(Date:8/20/2014)... A survey of U.S. veterans receiving mental health services ... also significant room for improvement among all areas studied. ... 2009, found that patients with a substance use disorder ... health services. Those with substance abuse problems also were ... to them or respected their decisions. , The findings, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 IQ Formulations ... was named to the Inc. 500 , distinguishing it ... United States. IQ Formulations not only made the list, but ... 5,486 percent over the past three years. It also ranked ... state of Florida and the second fastest growing company in ...
(Date:8/20/2014)... San Mateo, CA (PRWEB) August 20, 2014 ... their newest product—the Really Little Green Pouch —to ... easier to feed babies and toddlers homemade foods. ... says Little Green Pouch co-founder Maggie Crawford. She ... their kids, to limit exposure to things like pesticides ...
(Date:8/20/2014)... News) -- Taking the widely used antibiotic ... heart-related causes, a new study suggests. Because millions ... require urgent confirmation, said the Danish researchers behind the ... small and that guidelines for the use of the ... available. One heart expert wasn,t surprised by the ...
Breaking Medicine News(10 mins):Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Multiplexed Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Survey finds veterans generally satisfied with mental health care 2Health News:Leading Health Supplement Company IQ Formulations Among Inc. Magazine’s Top 50 Fastest Growing Private Companies in the United States 2Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2Health News:Antibiotic Might Raise Heart Risks for Some 2
... Outside Board Meeting, MARTINEZ, Calif., Nov. 26 ... place outside Tuesday,s meeting of the Contra,Costa Board ... The 150,000-member SEIU United Healthcare Workers-West is ... United States and represents,every type of healthcare worker, ...
... cholera, a potentially fatal,diarrheal disease found in the ... orally vaccinating half of the affected,populations once every ... to,new findings by an international team of researchers ... in the Vaccine and Infectious Disease,Institute at Fred ...
... experience stigma, loneliness and ostracism, and can find it ... new research findings. , They also struggle to ... though, in theory, there is 100% access to state-funded ... result. , Sarah Bernays, of the London School of ...
... 26 The Wackenhut,Corporation, the leading security services ... to enhance its employee medical and dental,insurance plans ... further validation that Wackenhut,s focus on employee welfare ... consulting firm, Mercer, released an overview of,its most ...
... ... Marine Underwriters, CANTON, Mass., Nov. 26 ... Southern Marine,& Aviation Inc., to represent its International Marine Underwriters (IMU),division. ... under a primary marine cargo program managed by Southern Marine &,Aviation, ...
... Datascope Urges Shareholders to Re-Elect Incumbent Directors and Reject ... ... Datascope Corp.,(Nasdaq: DSCP ) today filed an investor ... available on the Investor,Relations section of the Company,s website at ...
Cached Medicine News:Health News:Study Shows Cholera Can be Controlled With Oral Vaccines 2Health News:Study Shows Cholera Can be Controlled With Oral Vaccines 3Health News:New study highlights stigma and stress of living with HIV/AIDS in Serbia 2Health News:New study highlights stigma and stress of living with HIV/AIDS in Serbia 3Health News:Wackenhut Enhances Health Insurance Plans Without Raising Costs 2Health News:OneBeacon Appoints Southern Marine & Aviation Inc. 2Health News:OneBeacon Appoints Southern Marine & Aviation Inc. 3Health News:OneBeacon Appoints Southern Marine & Aviation Inc. 4Health News:Datascope Files Investor Presentation 2Health News:Datascope Files Investor Presentation 3Health News:Datascope Files Investor Presentation 4Health News:Datascope Files Investor Presentation 5Health News:Datascope Files Investor Presentation 6Health News:Datascope Files Investor Presentation 7Health News:Datascope Files Investor Presentation 8
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: